Biocon Limited (BIOCON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Biocon Limited (Biocon) is a global biopharmaceutical company specialized in biopharmaceuticals and research services. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations and biologicals. Its core therapeutic areas include anti-diabetics, cardiovascular, anti-inflammatory, anti-obesity, hepato-protective and gastro-intestinal drugs, nutraceuticals, digestive-aid enzymes, immunosuppressants and anti-oxidants. The company offers branded formulations in the fields of cardiology, diabetology, oncology, immunotherapy, nephrology and comprehensive care. The company also provides licensing, contract manufacturing and research services to biotechnology and pharmaceutical companies. It delivers research and development solutions to partners and customers across the world. Biocon is headquartered in Bangalore, Karnataka, India.
Biocon Limited Key Recent Developments
Jul 21, 2016: Biocon Reports a Strong Q1 FY17 Revenues at Rs. 952 Crore, Up by 11%; EBITDA Up 15% to Rs. 271 Crore; Net Profit Up 17% at Rs. 147 Crore
Apr 26, 2016: Biocon Q4FY16 Net Profit at Rs 361 Cr Revenue Crosses Rs 1,000 Cr; Up 17%
Apr 26, 2016: Biocon : Q4FY16 Net Profit at Rs 361 Cr; Revenue Crosses Rs 1,000 Cr; Up 17%
Jan 22, 2016: Biocon Announces Q3 results for the quarter ended December 31, 2015
Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10%
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
                     
                                   '
                        
Table of Contents
Table of Contents  2
List of Tables  4
List of Figures  5
Section 1 - About the Company  6
Biocon Limited - Key Facts  6
Biocon Limited - Key Employees  7
Biocon Limited - Key Employee Biographies  8
Biocon Limited - Major Products and Services  9
Biocon Limited - Pharmaceutical Pipeline Products Data  11
Biocon Limited, Pipeline Products by Therapy Area  11
Biocon Limited, Pipeline Products by Development Phase  12
Biocon Limited - History  15
Biocon Limited - Company Statement  21
Biocon Limited - Locations And Subsidiaries  25
Head Office  25
Other Locations & Subsidiaries  25
Section 2 – Company Analysis  27
Biocon Limited - Business Description  27
Biocon Limited - Corporate Strategy  28
Biocon Limited - SWOT Analysis  29
SWOT Analysis - Overview  29
Biocon Limited - Strengths  29
Strength - Focused Research & Development  29
Strength - Revenue Services and Core Biopharma  29
Strength - Strategic Agreements and Collaborations  29
Biocon Limited - Weaknesses  30
Weakness - Increased Credit Risk  30
Weakness - Patent Infringement Lawsuit  30
Biocon Limited - Opportunities  31
Opportunity - Strategic Initiatives  31
Opportunity - Product Pipeline  31
Opportunity - Branded Biologics Sales to Grow  31
Opportunity - New Approvals and Launches  31
Biocon Limited - Threats  32
Threat - Competitive Pressures  32
Threat - Government Regulations  32
Threat - Usage of Hazardous Materials  32
Biocon Limited - Key Competitors  33
Section 3 – Company Financial Ratios  34
Financial Ratios - Capital Market Ratios  34
Financial Ratios - Annual Ratios  35
Performance Chart  37
Financial Performance  37
Financial Ratios - Interim Ratios  38
Financial Ratios - Ratio Charts  39
Section 4 – Company’s Lifesciences Financial Deals and Alliances  40
Biocon Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  40
Biocon Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016  41
Biocon Limited, Recent Deals Summary  42
Section 5 – Company’s Recent Developments  43
Jul 21, 2016: Biocon Reports a Strong Q1 FY17 Revenues at Rs. 952 Crore, Up by 11%; EBITDA Up 15% to Rs. 271 Crore; Net Profit Up 17% at Rs. 147 Crore  43
Apr 26, 2016: Biocon Q4FY16 Net Profit at Rs 361 Cr Revenue Crosses Rs 1,000 Cr; Up 17%  46
Apr 26, 2016: Biocon : Q4FY16 Net Profit at Rs 361 Cr; Revenue Crosses Rs 1,000 Cr; Up 17%  49
Jan 22, 2016: Biocon Announces Q3 results for the quarter ended December 31, 2015  52
Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10%  53
Nov 03, 2015: Biocon is the Only Asian Company to be ranked in Top 20 Global Biotech Employers for 2015  56
Oct 20, 2015: Biocon Q2FY16 Revenues Up 12%; Net Profit Up 200% Syngene Delivers 30% Growth  57
Sep 15, 2015: Biocon Inaugurates World Class Devices Facility  59
Aug 24, 2015: Biocon Clarifies On FDA’s Inspection  60
Jul 23, 2015: Biocon's Earnings Surge in Q1 FY16; Revenue up by 15% at Rs. 857 Crore, Net Profit up by 23% at Rs. 126 Crore  61
Section 6 – Appendix  63
Methodology  63
Ratio Definitions  63
About GlobalData  67
Contact Us  67
Disclaimer  67
List of Tables
Biocon Limited, Key Facts  6
Biocon Limited, Key Employees  7
Biocon Limited, Key Employee Biographies  8
Biocon Limited, Major Products and Services  9
Biocon Limited, Number of Pipeline Products by Therapy Area  11
Biocon Limited, Number of Pipeline Products by Development Stage  12
Biocon Limited, Pipeline Products By Therapy Area and Development Phase  13
Biocon Limited, History  15
Biocon Limited, Other Locations  25
Biocon Limited, Subsidiaries  25
Biocon Limited, Key Competitors  33
Biocon Limited, Ratios based on current share price  34
Biocon Limited, Annual Ratios  35
Biocon Limited, Interim Ratios  38
Biocon Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  40
Biocon Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016  41
Biocon Limited, Recent Deals Summary  42
Currency Codes  63
Capital Market Ratios  63
Equity Ratios  64
Profitability Ratios  64
Cost Ratios  65
Liquidity Ratios  65
Leverage Ratios  66
Efficiency Ratios  66
List of Figures
Biocon Limited,  Pipeline Products by Therapy Area  11
Biocon Limited,  Pipeline Products by Development Phase  12
Biocon Limited, Performance Chart (2012 - 2016)  37
Biocon Limited, Ratio Charts  39
Biocon Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016  40
Biocon Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016  41